Edgar Schmitt Selected Research

Tetanus Toxoid (Vaccine, Tetanus)

1/2019	Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid.
4/2018	Synthetic MUC1 Antitumor Vaccine with Incorporated 2,3-Sialyl-T Carbohydrate Antigen Inducing Strong Immune Responses with Isotype Specificity.
1/2017	Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice.
4/2014	A fully synthetic glycopeptide antitumor vaccine based on multiple antigen presentation on a hyperbranched polymer.
9/2013	Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines.
10/2011	Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues.
1/2009	A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Edgar Schmitt Research Topics

Disease

28	Neoplasms (Cancer) 11/2021 - 11/2005
10	Breast Neoplasms (Breast Cancer) 01/2019 - 10/2011
9	Inflammation (Inflammations) 01/2021 - 01/2002
9	Asthma (Bronchial Asthma) 02/2015 - 02/2005
5	Infections 10/2016 - 05/2003
4	Hypersensitivity (Allergy) 01/2021 - 01/2002
3	Graft vs Host Disease (Graft-Versus-Host Disease) 06/2014 - 08/2009
3	Hepatitis 12/2007 - 05/2003
2	Parasitic Diseases (Parasitic Disease) 01/2021 - 01/2012
2	Autoimmune Diseases (Autoimmune Disease) 03/2017 - 11/2006
2	Respiratory Hypersensitivity 04/2009 - 08/2008
1	Pancreatic Neoplasms (Pancreatic Cancer) 02/2016
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2016
1	Body Weight (Weight, Body) 01/2016
1	Adenocarcinoma 04/2015
1	Lung Neoplasms (Lung Cancer) 04/2015
1	Neoplasm Metastasis (Metastasis) 01/2015
1	Chronic Hepatitis B 08/2013
1	Virus Diseases (Viral Diseases) 06/2013
1	Acute Kidney Injury (Acute Renal Failure) 03/2013
1	Chronic Kidney Failure (Chronic Renal Failure) 03/2013
1	Allergic Contact Dermatitis 09/2012
1	Contact Dermatitis (Eczema, Contact) 09/2012
1	Cardiomyopathies (Cardiomyopathy) 01/2012
1	Carcinoma (Carcinomatosis) 10/2011
1	Persistent Infection 01/2011
1	Premature Obstetric Labor (Premature Labor) 11/2010

Drug/Important Bio-Agent (IBA)

19	GlycopeptidesIBA 11/2021 - 11/2005
14	VaccinesIBA 11/2021 - 03/2007
12	AntigensIBA 01/2019 - 05/2003
10	Synthetic Vaccines (Recombinant Vaccines)IBA 01/2019 - 11/2005
9	AntibodiesIBA 01/2019 - 08/2006
8	CytokinesIBA 01/2021 - 11/2003
7	EpitopesIBA 11/2021 - 01/2011
7	Tetanus Toxoid (Vaccine, Tetanus)FDA Link 01/2019 - 01/2009
6	AllergensIBA 02/2015 - 05/2003
5	Peptides (Polypeptides)IBA 01/2019 - 01/2011
5	Glycoproteins (Glycoprotein)IBA 01/2019 - 01/2015
5	Immunoglobulin G (IgG)IBA 01/2018 - 05/2003
5	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 03/2015 - 11/2005
4	Mucin-1 (CA 15-3 Antigen)IBA 01/2019 - 02/2016
4	Immune Sera (Antisera)IBA 04/2018 - 03/2016
4	Interleukin-9 (Interleukin 9)IBA 03/2012 - 02/2007
3	Cancer VaccinesIBA 11/2021 - 04/2015
3	Monoclonal AntibodiesIBA 01/2019 - 01/2009
3	Interleukin-10 (Interleukin 10)IBA 02/2015 - 01/2011
3	Immunoglobulin E (IgE)IBA 01/2012 - 05/2003
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2012 - 11/2003
2	MucinsIBA 11/2021 - 04/2015
2	Neoplasm Antigens (Tumor Antigens)IBA 01/2019 - 03/2007
2	Tumor Viral Antigens (Large T Antigen)IBA 01/2019 - 03/2017
2	Polysaccharides (Glycans)IBA 04/2018 - 03/2017
2	GoldIBA 05/2017 - 03/2016
2	AutoantigensIBA 01/2017 - 09/2010
2	B-Lymphocyte Epitopes (B-Cell Epitope)IBA 03/2015 - 12/2014
2	HLA-DR Antigens (HLA-DR)IBA 03/2013 - 11/2010
2	Interleukin-2 (IL2)IBA 09/2012 - 08/2008
2	LigandsIBA 05/2010 - 08/2007
2	Histocompatibility Antigens Class IIIBA 12/2007 - 05/2003
1	Subunit VaccinesIBA 11/2021
1	Carbohydrate Tumor-Associated Antigens (Antigens, Tumor-Associated Carbohydrate)IBA 11/2021
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	Estrogen ReceptorsIBA 01/2019
1	Progesterone Receptors (Progesterone Receptor)IBA 01/2019
1	Immunoconjugates (Immunoconjugate)IBA 01/2019
1	Therapeutic UsesIBA 01/2019
1	Protein Subunit VaccinesIBA 04/2018
1	PolymersIBA 01/2018
1	Mannose (D-Mannose)IBA 01/2018
1	Cisplatin (Platino)FDA LinkGeneric 05/2017
1	Poly I-CIBA 01/2017
1	Indicators and Reagents (Reagents)IBA 02/2016
1	Biological ProductsIBA 02/2016
1	CholesterolIBA 01/2016
1	Casein Kinase II (Casein Kinase 2)IBA 01/2016
1	Tumor Biomarkers (Tumor Markers)IBA 04/2015
1	NanogelsIBA 03/2015
1	Tetanus ToxinIBA 03/2015
1	squaric acidIBA 12/2014
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 08/2014
1	polyglycerolIBA 04/2014
1	DuxonIBA 09/2013
1	Antiviral Agents (Antivirals)IBA 08/2013
1	DNA (Deoxyribonucleic Acid)IBA 06/2013
1	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2013
1	Cyclic NucleotidesIBA 01/2013
1	HaptensIBA 09/2012
1	Salivary Proteins and PeptidesIBA 03/2012
1	InterferonsIBA 01/2012
1	Immunodominant EpitopesIBA 10/2011
1	Imiquimod (Aldara)FDA LinkGeneric 01/2011
1	LipopeptidesIBA 05/2010

Therapy/Procedure

10	Immunotherapy 01/2018 - 03/2007
3	Therapeutics 01/2019 - 01/2007
2	Ligation 12/2014 - 09/2013
2	Transplantation 06/2014 - 11/2010
1	Cell Transplantation 10/2016
1	Organ Transplantation 10/2016
1	Cell- and Tissue-Based Therapy (Cell Therapy) 08/2013
1	Stem Cell Transplantation 01/2013